IL17RA (interleukin 17 receptor A) serves as the primary receptor for IL-17A and other IL-17 family cytokines, mediating key inflammatory and immune responses 1. The receptor belongs to a structurally unique cytokine receptor family with distinctive functional motifs and signaling pathways 1. IL17RA activation triggers downstream signaling cascades that promote pro-inflammatory cytokine production, including IL-6, IL-23, and chemokines, through NF-κB pathway activation 2. In cancer contexts, IL17RA exhibits complex dual functions: in colorectal cancer, it provides tumor-suppressive effects by preventing epithelial-to-mesenchymal transition in intestinal epithelial cells while enabling protective anti-tumor immunity in macrophages through Syk activation 3. Conversely, in pancreatic cancer, IL17RA signaling in fibroblasts promotes tumor progression by facilitating cancer-associated fibroblast activation and enhancing tumor cell proliferation 4. Clinically, IL17RA is a validated therapeutic target, with brodalumab (an IL-17RA-blocking antibody) approved for psoriasis treatment 5. The receptor shows tissue-specific expression patterns, being identified in various cell types including mesenchymal cells, monocytes, and T cells in fibrotic liver tissue 6. IL17RA deficiency is associated with immunodeficiency disorders, highlighting its essential role in host defense mechanisms.